News | January 22, 2014

BioVentrix takes treatment to second European location

Implant of Revivent-TC Ventricular Enhancement System done in Czech Republic

BioVentrix Revivent-TC Heart Failure Treatment Cath Lab Structural Heart
January 22, 2014 — BioVentrix’s Revivent-TC Ventricular Enhancement System was implanted in a man via Less Invasive Ventricular Enhancement (LIVE) in Prague, Czech Republic. 
The procedure, which is used to reshape and reduce the left ventricle, was performed on a 64-year-old man suffering from ischemic heart failure.  Prof. Petr Neuzil and Dr. Ivo Skalsky performed the transcatheter procedure at Na Holmoce Hospital without opening the patient’s chest or using a heart-lung bypass machine.
“The Revivent-TC hybrid system allows treatment of both worsening heart failure patients, and those who are already very ill, without opening the chest,” said Neuzil, head of cardiology and director of the cardiac arrhythmia service. “This is a major breakthrough for this patient population that will lower the barrier to intervention for all heart failure classifications.”
Within three days of the LIVE procedure, the patient’s ejection fraction improved 45 percent improvement, rising from a 31 percent preoperative measurement.
For more information:

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init